Fox Chase Cancer Center Welcomes Geneviève Almouzni to the External Advisory Board of the Cancer Epigenetics Institute

Geneviève Almouzni, PhD, a world leader in understanding genome organization and function during development and disease, has joined the External Advisory Board of the Cancer Epigenetics Institute. Photo Attribution: ©Elisabetta Citterio, STEM passion project

PHILADELPHIA (November 26, 2024) - Fox Chase Cancer Center is pleased to announce that Geneviève Almouzni, PhD, is joining the External Advisory Board of the Cancer Epigenetics Institute (CEI).

"It is my great pleasure and honor to join the advisory board for the CEI," said Almouzni. "Its strong research program, along with its recruitment of talented new faculty and promising postdoctoral fellows and graduate students, have made for a vibrant scientific community. I have been following its work and look forward to contributing to its continued success."

The CEI at Fox Chase is a locally based national hub dedicated to epigenetic studies and collaborations that focuses on mechanisms that promote cancer and therapeutic resistance. The CEI's goal is to achieve further discovery in cancer epigenetics by enhancing academic-to-academic and academic-to-industry relationships. Advisory board members like Almouzni help foster these developments and encourage new opportunities.

"We are thrilled to have Dr. Almouzni join our advisory board. She is a world leader in epigenetics and bringing her vast experience to the table will greatly enhance our program. She is also a great mentor and interested in helping us advance the next generation of faculty and trainees," said Johnathan Whetstine, PhD, Director of the CEI and the Jack Schultz Chair in Basic Science at Fox Chase.

"We also would like to thank Dr. Dent, who was an inaugural External Advisory Board member, for her time and guidance with the launch of the CEI in 2021," Whetstine added. Sharon Y.R. Dent, PhD, Professor Emeritus in the Department of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center in Houston, is stepping down but will continue to serve as an emeritus member of the advisory board.

Almouzni was one of the keynote speakers at the Fox Chase Cancer Epigenetics Symposium in March. She is a member of the French Academy of Sciences and a Fellow of the American Association for the Advancement of Sciences. She was Director of the Research Center of the Institute Curie in Paris from 2013 to 2018 and has been Honorary Director since then.

She is a world leader in understanding genome organization and function during development and disease, with a particular focus on cancer. At the Institute Curie, she has combined biochemistry, cell biology, and physical approaches with advanced imaging to explore chromatin dynamics.

Throughout her career, Almouzni has earned a number of distinctions and awards, including Officer of the Legion of Honor and of the Merit Order, Knight of the Academic Palms, Women in Science Award from FEBS/EMBO, and L'Oréal-UNESCO International Award for Women in Science.